Synovial inflammation and bone metabolism

Javier Narváez García

PRINCIPAL INVESTIGATORS
  • Diego Benavent Nuñez
  • Laura Berbel Arcobe
  • Carmen Gómez Vaquero
  • Francisco Javier Juanola Roura
  • José Antonio Narváez García
  • Juan Miguel Nolla Sole
CLINICAL RESEARCHERS
  • Pol Maymo Paituvi
  • Carmen Moragues Pastor
  • José Miguel Ruiz Martín
  • Jessica Ruiz Toledo
  • Lidia Valencia Muntala
  • Paola Vidal Montal
POSTDOCTORAL RESEARCHERS
  • Marta Vinyals Rodriguez
SCIENTIFIC SUPPORT
  • Daniel Fontes Carame
Translational Medicine
Cardiovascular, Respiratory and Systemic Diseases and cellular aging

Scientific production

56

PAPERS

Average IF: 3,65

27

LED PAPERS

Average IF: 3,66

2 PUBLICATIONS IN FIRST DECILE

35 PUBLICATIONS IN FIRST QUARTILE

26PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Narváez,J;Aguilar Coll,M;Roig Kim,M;Palacios Olid,J;Maymó Paituvi,P;de Daniel Bisbe,L;LLop,D, Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis., Autoimmun Rev, 2025;24(6):103804-103804, doi:10.1016/j.autrev.2025.103804
  • Perez Recio,S;Grijota Camino,MD;Guardiola,J;Juanola,X;Notario,J;Solanich,X;Rodriguez Moranta,F et al, Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years’ Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country, Clin Infect Dis, 2025;doi:10.1093/cid/ciaf491
  • Batista Liz,JC;Calvo Rio,V;Mora Gil,MS;Leonardo,MT;Peñalba,AC;Martin Penagos,L;Narvaez,J et al, Evaluating the usefulness of C5 and C5AR1 as genetic biomarkers of IgA-mediated vasculitis, Mol Med, 2025;31(1):267-267, doi:10.1186/s10020-025-01313-3
  • Batista Liz,JC;Mora Gil,MS;García,MR;Leonardo,MT;Peñalba,A;Gabrie,L;Sanchez,RG et al, The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis, Front. Immunol., 2025;161692908-1692908, doi:10.3389/fimmu.2025.1692908
  • Montoya Garcia,MJ;Carbonell Abella,C;Garcia,MG;Hernandez Cruz,B;Gomez Vaquero,C;Naranjo,A;Aviñó,RI et al, Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry, Osteoporosis Int., 2025;36(11):2245-2255, doi:10.1007/s00198-025-07565-3

Research highlights

PROJECTS

1 Ongoing competitive project

7 Started clinical trials
18 Ongoing clinical trials

PUBLISHED WORKS

2 Clinical Guidelines
1 Thesis

Selected projects

  • AP176692021. Caracterización del eStroMa inflAmatoRio en meTástasis ósEas de cáncer de próstata resistente a castración utilizando técnicas de secuenciación de células individuales y correlación con diferentes patrones radiómicos utilizando Resonancia magnética de dif. Fundación Mutua Madrileña (FMM), AYUDAS A LA INVESTIGACIÓN EN SALUD 2019. Budget: 150.000€. 2021-2025. PI: JOSÉ ANTONIO NARVÁEZ GARCÍA.
  • LG-GDCL010. A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients with Hyperuricemia. IDIBELL (Institut d’Investigació Biomédica de Bellvitge). Budget: 102.877,65€. 2024-2025. PI: CARMEN MORAGUES PASTOR.
  • 77242113PSA3002. Estudio fase 3 multicéntrico, aleatorizado, doble ciego y controlado con placebo que evalúa la eficacia y la seguridad de JNJ-77242113 para el tratamiento de pacientes con artritis psoriásica activa con tratamiento biológico previo.. JANSSEN RESEARCH & DEVELOPMENT LLC. Budget: 56.700€. 2025- . PI: LAURA BERBEL ARCOBE.
    D3463C00003. A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis).. AstraZeneca AB. Budget: 41.118,9€. 2024- . PI: PAOLA VIDAL MONTAL.
  • 1305-0046. A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD). Boehringer Ingelheim International GmbH. Budget: 31.647€. 2025- . PI: FRANCISCO JAVIER NARVAEZ GARCIA.